{
    "root": "3417f51c-7ace-49a1-ab3e-d14de2384c71",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Rosuvastatin Calcium",
    "value": "20250228",
    "ingredients": [
        {
            "name": "ROSUVASTATIN CALCIUM",
            "code": "83MVU38M7Q"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "Anhydrous Dibasic Calcium Phosphate",
            "code": "L11K75P92J"
        },
        {
            "name": "Crospovidone",
            "code": "2S7830E561"
        },
        {
            "name": "Magnesium Stearate",
            "code": "70097M6I30"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "CROSPOVIDONE",
            "code": "2S7830E561"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        }
    ],
    "indications": "rosuvastatin tablets indicated : • reduce risk major cardiovascular ( cv ) events ( cv death , nonfatal myocardial infarction , nonfatal stroke , arterial revascularization procedure ) adults without established coronary heart disease increased risk cv disease based age , high-sensitivity c-reactive protein ( hscrp ) ≥2 mg/l , least one additional cv risk factor.• adjunct diet : º reduce low-density lipoprotein cholesterol ( ldl-c ) adults primary hyperlipidemia.º reduce ldl-c slow progression atherosclerosis adults.º reduce ldl-c adults pediatric patients aged 8 years older heterozygous familial hypercholesterolemia ( hefh ) . • adjunct ldl-c-lowering therapies , alone treatments unavailable , reduce ldl-c adults pediatric patients aged 7 years older homozygous familial hypercholesterolemia ( hofh ) . • adjunct diet treatment adults : º primary dysbetalipoproteinemia.º hypertriglyceridemia .",
    "contraindications": "take orally without food , time day . ( 2.1 ) assess ldl-c clinically appropriate , early 4 weeks initiating rosuvastatin tablets , adjust necessary . ( 2.1 ) adults : recommended range 5 40 mg daily . ( 2.1 ) pediatric patients hefh : recommended range 5 10 mg daily patients aged 8 less 10 years age , 5 20 mg daily patients aged 10 years older . ( 2.2 ) pediatric patients hofh : recommended 20 mg daily patients aged 7 years older . ( 2.2 ) asian patients : initiate 5 mg daily . consider risks benefits treatment adequately controlled doses 20 mg daily . ( 2.4 ) patients severe renal impairment ( hemodialysis ) : initiate 5 mg daily ; exceed 10 mg daily . ( 2.5 ) full prescribing information rosuvastatin tablets modifications due . ( 2.6 )",
    "warningsAndPrecautions": "rosuvastatin tablets supplied : ndc 69434-005-02 : 5mg . round , yellow film coated tablet , biconvex , one side tablet debossed “ y16 ” , side smooth ; bottle 90 tablets.ndc 69434-005-03 : 5mg . round , yellow film coated tablet , biconvex , one side tablet debossed “ y16 ” , side smooth ; bottle 500 tablets . ndc 69434-006-02 : 10 mg. round , pink film coated tablet , biconvex , one side tablet debossed “ y17 ” , side smooth ; bottle 90 tablets.ndc 69434-006-03 : 10 mg. round , pink film coated tablet , biconvex , one side tablet debossed “ y17 ” , side smooth ; bottle 500 tablets . ndc 69434-007-02 : 20 mg. round , yellow film coated tablet , biconvex , one side tablet debossed “ y19 ” , side smooth ; bottle 90 tablets.ndc 69434-007-03 : 20 mg. round , yellow film coated tablet , biconvex , one side tablet debossed “ y19 ” , side smooth ; bottle 500 tablets . ndc 69434-008-01 : 40 mg. round , pink film coated tablet , biconvex , one side tablet debossed “ y20 ” , side smooth ; bottle 30 tablets.ndc 69434-008-03 : 40 mg. round , pink film coated tablet , biconvex , one side tablet debossed “ y20 ” , side smooth ; bottle 500 tablets . storage store controlled room temperature , 20ºc 25ºc ( 68ºf 77ºf ) ; excursions permitted 15°c 30°c ( 59°f 86°f ) [ usp controlled room temperature ] . protect moisture .",
    "adverseReactions": "rosuvastatin tablets contraindicated following conditions : • acute liver failure decompensated cirrhosis [ ( 5.3 ) ] . •hypersensitivity rosuvastatin excipients rosuvastatin tablets . hypersensitivity including rash , pruritus , urticaria , angioedema reported rosuvastatin tablets [ ( 6.1 ) ] .",
    "indications_original": "Rosuvastatin tablets are indicated:• To reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults without established coronary heart disease who are at increased risk of CV disease based on age, high-sensitivity C-reactive protein (hsCRP) ≥2 mg/L, and at least one additional CV risk factor.• As an adjunct to diet to:º Reduce low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia.º Reduce LDL-C and slow the progression of atherosclerosis in adults.º Reduce LDL-C in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH).• As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH).• As an adjunct to diet for the treatment of adults with:º Primary dysbetalipoproteinemia.º Hypertriglyceridemia.",
    "contraindications_original": "Take orally with or without food, at any time of day. ( 2.1 ) Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating ROSUVASTATIN TABLETS, and adjust dosage if necessary. ( 2.1 ) Adults: Recommended dosage range is 5 to 40 mg once daily. ( 2.1 ) Pediatric Patients with HeFH: Recommended dosage range is 5 to 10 mg once daily for patients aged 8 to less than 10 years of age, and 5 to 20 mg once daily for patients aged 10 years and older. ( 2.2 ) Pediatric Patients with HoFH: Recommended dosage is 20 mg once daily for patients aged 7 years and older. ( 2.2 ) Asian Patients: Initiate at 5 mg once daily. Consider risks and benefits of treatment if not adequately controlled at doses up to 20 mg once daily. ( 2.4 ) Patients with Severe Renal Impairment (not on hemodialysis): Initiate at 5 mg once daily; do not exceed 10 mg once daily. ( 2.5 ) See full prescribing information for ROSUVASTATIN TABLETS dosage and administration modifications due to drug interactions. ( 2.6 )",
    "warningsAndPrecautions_original": "Rosuvastatin tablets are supplied as:\n                  NDC 69434-005-02: 5mg. Round, yellow film coated tablet, biconvex, one side of the tablet debossed“Y16”, the other side is smooth; bottle of 90 tablets.NDC 69434-005-03: 5mg. Round, yellow film coated tablet, biconvex, one side of the tablet debossed “Y16”, the other side is smooth; bottle of 500 tablets.\n                  NDC 69434-006-02: 10 mg. Round, pink film coated tablet, biconvex, one side of the tablet debossed “Y17”, the other side is smooth; bottle of 90 tablets.NDC 69434-006-03: 10 mg. Round, pink film coated tablet, biconvex, one side of the tablet debossed “Y17”, the other side is smooth; bottle of 500 tablets.\n                  NDC 69434-007-02: 20 mg. Round, yellow film coated tablet, biconvex, one side of the tablet debossed “Y19”, the other side is smooth; bottle of 90 tablets.NDC 69434-007-03: 20 mg. Round, yellow film coated tablet, biconvex, one side of the tablet debossed “Y19”, the other side is smooth; bottle of 500 tablets.\n                  NDC 69434-008-01: 40 mg. Round, pink film coated tablet, biconvex, one side of the tablet debossed “Y20”, the other side is smooth; bottle of 30 tablets.NDC 69434-008-03: 40 mg. Round, pink film coated tablet, biconvex, one side of the tablet debossed “Y20”, the other side is smooth; bottle of 500 tablets.\n                  \n                     Storage\n                  \n                  Store at controlled room temperature, 20ºC to 25ºC (68ºF to 77ºF); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature]. Protect from moisture.",
    "adverseReactions_original": "Rosuvastatin tablets are contraindicated in the following conditions:\n                  • Acute liver failure or decompensated cirrhosis [see Warnings and Precautions (5.3)].\n                  •Hypersensitivity to rosuvastatin or any excipients in rosuvastatin tablets. Hypersensitivity reactions including rash, pruritus, urticaria, and angioedema have been reported with rosuvastatin tablets [see Adverse Reactions (6.1)]."
}